Impower010 nct02486718
Witryna20 wrz 2024 · Exploratory results from the phase 3 IMpower010 trial (NCT02486718) show that adjuvant treatment with atezolizumab (Tecentriq) achieved an improvement in disease-free survival (DFS) and time to locoregional and distant relapse compared with best supportive care (BSC) in prespecified subgroups of PD-L1–positive patients with … Witryna9 paź 2024 · IMpower010 is registered with ClinicalTrials.gov, NCT02486718 (active, not recruiting). Findings: Between Oct 7, 2015, and Sept 19, 2024, 1280 patients were …
Impower010 nct02486718
Did you know?
Witryna1 wrz 2024 · IMpower010 (NCT02486718) was the first Phase III immunotherapy study to show a statistically significant disease-free survival (DFS) benefit with adjuvant … Witryna• In IMpower010 (NCT02486718), adjuvant atezolizumab demonstrated a statistically significant DFS benefit vs BSC in resected NSCLC following platinum-based chemotherapy at the DFS IA 1 – PD-L1 TC ≥1% stage II-IIIA population analysis: DFS HR, 0.66; 95% CI: 0.50, 0.88
Witryna23 mar 2024 · IMpower010 is a global, multicenter, open-label, randomized trial (NCT02486718), which is comparing the safety and efficacy of atezolizumab and BSC … WitrynaPrevious findings from the Phase III IMpower010 ( NCT02486718) trial demonstrated a statistically significant improved disease-free survival (DFS) with atezolizumab compared to best supportive care (BSC) in patients with resected PD-L1 TC ≥1% stage II-IIIA non-small cell lung cancer (NSCLC) following platinum-based chemotherapy. 5 The …
http://www.zgazyw.com/Article/20240413223434-7484_1.html Witryna28 maj 2024 · We report the primary disease-free survival (DFS) results from the pre-planned interim analysis of IMpower010, a randomized phase 3 open-label trial of …
Witryna近日,中国国家药品监督管理局（nmpa）已受理君实抗pd-1单抗药物特瑞普利单抗的新适应症上市申请,即联合化疗围手术期治疗并本品单药作为辅助治疗后巩固治疗,用于可切除iii期非小细胞肺癌（nsclc）的治疗。这是特瑞普利单抗在中国递交的第7项上市申请。也有望成为首个治疗可手术肺癌的国产pd1。
WitrynaIMpower010 (NCT02486718) showed that adjuvant atezo improved disease-free survival (DFS) vs BSC in pts with PD-L1 tumour cell (TC) ≥1% stage II-IIIA NSCLC. While a … ctc offroadWitryna10 wrz 2024 · IMpower010 (NCT02486718) enrolled patients with completely resected, stage IB to IIIA NSCLC with an ECOG performance status of 0 or 1, who had undergone lobectomy/pneumonectomy, and had tumor tissue available for PD-L1 analysis. If patients had stage IB tumors, they had to be 4 cm or greater. ct cobia boatsWitrynaIMpower010 (NCT02486718) showed that adjuvant atezo improved disease-free survival (DFS) vs BSC in pts with PD-L1 tumour cell (TC) ≥1% stage II-IIIA NSCLC. While a … ct coastal gynWitrynaIMpower010 (NCT02486718). 40: Patients with stage IB–IIIA NSCLC: A phase III, multicenter, open-label, randomized study: In patients with stage IB-IIIA NSCLC following resection and adjuvant chemotherapy, the study compares the efficacy and safety of 16 cycles of atezolizumab treatment compared with supportive care. Primary outcomes: … ctc nursing programsWitryna2 gru 2024 · Adjuvant atezolizumab (Tecentriq) outperformed best supportive care according to results from the phase 3 IMpower010 trial (NCT02486718), which supported FDA approval of the agent for patients ... earth absorbs moreWitryna29 wrz 2024 · Peters highlight the importance of the phase 3 IMpower010 trial (NCT02486718), which examined the use of adjuvant atezolizumab (Tecentriq) in patients with non–small cell lung cancer, as well as the phase 2 FIRSTMAPP trial, which examined the use of sunitinib (Sutent) in pheochromocytoma and paraganglioma … ct coaching certification onlinect coastal rentals